Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium

Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/11...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yuanhong, Wu, Siyu, Li, Rong, Yu, Jiazheng, Zheng, Jianyi, Li, Zeyu, Li, Mingyang, Xin, Kerong, Xu, Zhenqun, Li, Shijie, Chen, Xiaonan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391859/
https://www.ncbi.nlm.nih.gov/pubmed/37528464
http://dx.doi.org/10.1186/s40164-023-00430-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391859/
https://www.ncbi.nlm.nih.gov/pubmed/37528464
http://dx.doi.org/10.1186/s40164-023-00430-1

Ejemplares similares